跳至主要内容
临床试验/CTIS2023-508298-10-00
CTIS2023-508298-10-00招募中1 期

Haemodynamic Effects of Dobutamine in Patients with Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

Region Midtjylland0 个研究点目标入组 35 人开始时间: 2023年9月20日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
65 至 65+(—)
性别
All

入选标准

  • ATTRwt, diagnosis confirmed by genetic testing, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and/or endomyocardial biopsy., Treated with loop diuretics., New York Heart Association (NYHA) class II-IV., Age = 65 years., Left ventricular ejection fraction (LVEF) < 50 % and/or SVI assessed by echocardiography < 35 ml/m2., Informed consent.

排除标准

  • Moderate to severe aortic stenosis (patients with aortic sclerosis will not be excluded)., Other significant valvular diseases., Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, or recent acute myocardial infarction (< 4 weeks)., Contraindications to the use of dobutamine: Known allergy to dobutamine or sulfite, phaeochromocytoma or ventricular tachycardia (VT).

研究者

发起方
Region Midtjylland

相似试验